SG10201804257RA - Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells - Google Patents

Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

Info

Publication number
SG10201804257RA
SG10201804257RA SG10201804257RA SG10201804257RA SG10201804257RA SG 10201804257R A SG10201804257R A SG 10201804257RA SG 10201804257R A SG10201804257R A SG 10201804257RA SG 10201804257R A SG10201804257R A SG 10201804257RA SG 10201804257R A SG10201804257R A SG 10201804257RA
Authority
SG
Singapore
Prior art keywords
nucleic acid
functional nucleic
bacterially
derived
mammalian cells
Prior art date
Application number
SG10201804257RA
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Toby Hulf
Original Assignee
Engeneic Molecular Delivery Pty Ltd Au
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd Au filed Critical Engeneic Molecular Delivery Pty Ltd Au
Publication of SG10201804257RA publication Critical patent/SG10201804257RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11021—Polo kinase (2.7.11.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Abstract

BACTERIALLY-DERIVED, INTACT MINICELLS THAT ENCOMPASS PLASMID-FREE FUNCTIONAL NUCLEIC ACID FOR IN VIVO DELIVERY TO MAMMALIAN CELLS Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation. [FIG. ] 60
SG10201804257RA 2007-03-30 2008-03-26 Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells SG10201804257RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90907407P 2007-03-30 2007-03-30

Publications (1)

Publication Number Publication Date
SG10201804257RA true SG10201804257RA (en) 2018-06-28

Family

ID=40386454

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201507969PA SG10201507969PA (en) 2007-03-30 2008-03-26 Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
SG10201804257RA SG10201804257RA (en) 2007-03-30 2008-03-26 Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201507969PA SG10201507969PA (en) 2007-03-30 2008-03-26 Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

Country Status (18)

Country Link
EP (5) EP3205724B1 (en)
JP (1) JP5167338B2 (en)
CN (2) CN101715489B (en)
AU (1) AU2008291833B2 (en)
CA (3) CA2844647C (en)
CY (1) CY1119031T1 (en)
DK (2) DK2145002T3 (en)
ES (2) ES2626179T3 (en)
HK (2) HK1138326A1 (en)
HR (2) HRP20150328T1 (en)
LT (1) LT2865755T (en)
MX (1) MX2009010411A (en)
NZ (1) NZ580487A (en)
PL (2) PL2145002T3 (en)
PT (2) PT2865755T (en)
SG (2) SG10201507969PA (en)
SI (2) SI2145002T1 (en)
WO (1) WO2009027830A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102921019B (en) 2004-08-26 2015-04-01 恩杰内克分子递送有限公司 Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
WO2009027830A2 (en) * 2007-03-30 2009-03-05 Engeneic Molecular Delivery Pty Ltd. Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
DE102009017908A1 (en) * 2009-04-17 2010-10-21 Kist-Europe Forschungsgesellschaft Mbh Vector for the transport of microbiological organisms to disease centers
EP2478101A1 (en) * 2009-09-16 2012-07-25 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
SG11201403062YA (en) 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
US9006200B2 (en) * 2013-03-13 2015-04-14 Asbestos Diseases Research Foundation MicroRNA-based approach to treating malignant pleural mesothelioma
BR112016007100A2 (en) 2013-10-04 2017-08-01 Engeneic Molecular Delivery Pty Ltd combined tumor treatment using interferon gamma and bispecific ligand drug-loaded minicells
EP3200765A4 (en) * 2014-10-03 2018-05-30 EnGeneIC Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
MA46469A (en) 2016-10-06 2019-08-14 Engeneic Molecular Delivery Pty Ltd BACTERIAL TINICELLS FOR THE ADMINISTRATION OF NUCLEIC ACID ADJUVANTS AND THEIR METHODS OF USE
BR112019022539A2 (en) 2017-04-28 2020-06-16 Agrospheres, Inc. COMPOSITIONS AND METHODS FOR ENCAPSULATION AND SCALE DELIVERY OF AGORCHEMISTS
EP3615082A4 (en) 2017-04-28 2021-05-26 Agrospheres, Inc. Compositions and methods for enzyme immobilization
BR112020005803A2 (en) * 2017-09-25 2020-12-01 Agrospheres, Inc. compositions and methods for the modular production and administration of biological products
SG11202100507PA (en) 2018-07-23 2021-02-25 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
EP4061802A4 (en) * 2019-12-23 2024-01-24 Agrospheres Inc Compositions and methods for enhanced uptake of active ingredients for animal health and nutrition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
IL146206A0 (en) 1999-05-11 2002-07-25 Ortho Mcneil Pharm Inc Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
CN102172406B (en) 2001-10-15 2013-03-13 恩吉尼克分子传递私人有限公司 Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo
US20040053289A1 (en) * 2002-09-09 2004-03-18 The Regents Of The University Of California Short interfering nucleic acid hybrids and methods thereof
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
DK1694361T3 (en) 2003-12-09 2011-06-06 Engeneic Molecular Delivery Pty Ltd Targeted delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
NZ549139A (en) 2004-02-02 2009-11-27 Engeneic Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
CN102921019B (en) * 2004-08-26 2015-04-01 恩杰内克分子递送有限公司 Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
WO2009027830A2 (en) * 2007-03-30 2009-03-05 Engeneic Molecular Delivery Pty Ltd. Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells

Also Published As

Publication number Publication date
EP3205724B1 (en) 2019-05-08
WO2009027830A3 (en) 2009-05-14
CA2844647C (en) 2016-07-26
EP2532746A2 (en) 2012-12-12
EP2865755B1 (en) 2017-02-01
CN105854029B (en) 2019-10-18
EP2865755A2 (en) 2015-04-29
PL2145002T3 (en) 2015-06-30
HK1209786A1 (en) 2016-04-08
CN105854029A (en) 2016-08-17
HK1138326A1 (en) 2010-08-20
HRP20170662T1 (en) 2017-07-14
EP2865755A3 (en) 2015-05-06
EP2145002A2 (en) 2010-01-20
LT2865755T (en) 2017-07-25
CN101715489A (en) 2010-05-26
EP3205724A1 (en) 2017-08-16
EP2532746A3 (en) 2013-08-14
PT2865755T (en) 2017-05-26
CA2933978A1 (en) 2009-03-05
JP2010523487A (en) 2010-07-15
WO2009027830A2 (en) 2009-03-05
PL2865755T3 (en) 2017-08-31
CA2682704C (en) 2014-07-08
CY1119031T1 (en) 2018-01-10
SG10201507969PA (en) 2015-10-29
HRP20150328T1 (en) 2015-05-22
DK2145002T3 (en) 2015-04-20
CN101715489B (en) 2016-05-25
ES2534435T3 (en) 2015-04-22
PT2145002E (en) 2015-04-29
CA2844647A1 (en) 2009-03-05
AU2008291833B2 (en) 2012-11-08
SI2865755T1 (en) 2017-06-30
CA2682704A1 (en) 2009-03-05
DK2865755T3 (en) 2017-05-15
NZ580487A (en) 2012-04-27
SI2145002T1 (en) 2015-05-29
ES2626179T3 (en) 2017-07-24
CA2933978C (en) 2018-08-21
EP3564372A1 (en) 2019-11-06
AU2008291833A1 (en) 2009-03-05
JP5167338B2 (en) 2013-03-21
MX2009010411A (en) 2009-11-23
EP2145002B1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
SG10201804257RA (en) Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
WO2010099383A3 (en) Compositions and methods for ex vivo hepatic nucleic acid delivery
WO2011072246A3 (en) Tal effector-mediated dna modification
MX2010008099A (en) Stabilized angiopoietin-2 antibodies and uses thereof.
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
IN2014MN02141A (en)
MX351043B (en) Methods for genomic modification.
HK1163160A1 (en) Delivering functional nucleic acids to mammalian cells via bacterially- derived, intact minicells
WO2009058913A3 (en) Yeast cell wall protein (ycwp) encapsulated multilyered nanoparticles for nucleic acid delivery (sirna)
MX2009009371A (en) Enhanced production of fatty acid derivatives.
MX2010005451A (en) System for delivery into a xcr1 positive cell and uses thereof.
WO2005079532A3 (en) Methods and compositions for enhancing risc activity in vitro and in vivo
EP4241854A3 (en) Lysosomal storage disease enzyme
IN2015MN00436A (en)
WO2008121894A3 (en) Endogenous expression of hla-g and/or hla-e by mesenchymal cells
EP2576804A4 (en) Pentose fermentation by a recombinant microorganism
MX2009006681A (en) Compositions and methods for the expression of nucleic acids.
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
WO2010046493A3 (en) Gene transfer vectors comprising at least one isolated dna molecule having insulator and or boundary properties and methods to identify the same
EP2299530A4 (en) Novel enzyme electrode, and fuel cell comprising the enzyme electrode
MY171316A (en) Expression vector for animal cells
MX2016008568A (en) Compositions and methods for providing active telomerase to cells in vivo.
MY171359A (en) Pentose fermenting microorganisms